VOR (vorbio.com) Earnings per share growth this year

Vor Biopharma Inc. (VOR) possesses a colossal pricing advantage due to its unique genetic cell editing. The year-over-year growth in earnings per share reflects the asset's dynamics, where 88.10 serves as the final level mark. The sector is shielded from macroeconomic shocks by stable demand for innovation. Patents in the field of healthy tissue protection guarantee the company multi-year monopoly returns.

VOR: Vor Biopharma Inc. Earnings per share growth in current year 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for Vor Biopharma Inc. (VOR)

- stock value and consensus price forecast:

Market Price Vor Biopharma, Inc.|VOR - Analyst Consensus Forecast

- business market valuation indicators:

Market Capitalization Vor Bio Inc.|VOR - Real Price to Acquire Entire Company

- book capitalization information:

Net Assets per Single Share Vor Biopharma|VOR - Company Book Value|Market-to-Book Ratio vorbio.com|VOR - Aggregate Company Assets

- debt and solvency information:

- earnings and valuation multiples information:

VOR - Company Net Income|Forward Earnings Vor Biopharma Inc.|VOR - P/E Multiple|Future Price to Earnings Multiple Vor Bio Inc.|VOR - PEG Multiple|EV/EBITDA Multiple Vor Bio Inc.|VOR - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Vor Biopharma|VOR - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months vorbio.com|VOR - Earnings growth in current year|Earnings growth forecast for next year Vor Biopharma Inc.

- revenue and sales proceeds data:

VOR - Company Sales|Company Future Revenue Vor Biopharma, Inc.|VOR - P/S Multiple|Market Cap to Expected Sales Ratio Vor Bio Inc.

Fundamental valuation:Vor Biopharma, Inc., VOR

Vor Biopharma Inc. (VOR) bets on the organic development of oncology programs through scientific collaborations, making profit dynamics a key marker for R&D spending efficiency. By analyzing the proportional growth of EPS compared to last year on GURU.Markets, an investor assesses the percentage change in net income per share, which helps identify the business's maturity stage and detect a dangerous slowdown in capital expansion in a timely manner.

Direct competitors

Earnings per share growth rate in current year TG Therapeutics Inc (TGTX)|ACLX (Arcellx Corp) - Earnings growth in current year|Earnings per share growth this year IRON (Disc Medicine Pharma)|Net earnings per share growth this year SNDX (Syndax Pharmaceuticals)|Earnings per share growth in current year KURA (kuraoncology.com)|Earnings per share growth in current year ADC Therapeutics SA ADCT|Foghorn Therapeutics, Inc. (FHTX) - Earnings per share growth rate in current year|NKTX - Earnings per share growth in current year|Earnings per share increase in current year COEP (Coeptis Therapeutics)|ATNM (Actinium Pharmaceuticals) - Net earnings per share growth this year|estrellabio.com - Earnings per share increase in current year|CASI (CASI Pharmaceuticals Inc.) - Earnings growth in current year|Earnings per share growth in current year MRKR|Earnings growth in current year INAB|Expected net earnings per share growth this year eternatx.com|Earnings per share growth in current year GT Biopharma, Inc. GTBP|Aptose Biosciences Inc (APTO) - Earnings per share growth rate in current year|BPTH - Earnings per share growth in current year|Earnings per share trend in current year MEIP|VINC: Earnings growth in current year